Abstract Bilobar colorectal liver metastases (BCRLM) present a challenging scenario for liver surgeons globally. The following article aims to provide an overview of the different strategies which may be utilised in order to successfully manage advanced BCRLM.
Introduction
Colorectal cancer (CRC) is the fourth most common cancer in the UK [1] and the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012 [2] . Survival is highly dependent upon stage of disease at diagnosis, ranging from 90% 5-year survival for cancers diagnosed at the local stage to 10% for those diagnosed with distant metastatic disease [3] . Approximately 25% of patients with primary CRC are found to have synchronous hepatic metastases at the time of diagnosis [4] , and almost half of patients undergoing resection for primary CRC will eventually develop metachronous liver metastases (colorectal liver metastases (CRLM)) [5] . Median survival without treatment is 8 months from presentation, but prognosis is better for those patients with resectable hepatic metastases [6] .
The options for treatment of bilobar (bilobar CLRM (BCRLM)) have expanded over a relatively short time frame, from single unilobar metastases in the early 1990s to more extended resections over the last decade. This review article aims to explore current treatment options for patients with bilobar CRLM.
Treatment Strategies for Bilobar Metastases
Accurate preoperative staging of BCRLM is paramount to typify site, size and suitability for treatment [7] , with particular scrutiny given to the volume of the affected/unaffected liver from which treatment options will be directed. Techniques such as computed tomography volumetry and liver scintillography measurements are sometimes used to aid decision making regarding resectability [8, 9] . If the future remnant liver volume is predicted to be insufficient following resection (generally regarded to be less than 30% in a normal liver), then other treatment modalities could be considered. Care is also needed in accurate preoperative testing of patient fitness, modern cardiopulmonary exercise tolerance testing is utilised to ensure the patient is appropriately fit for the intervention proposed. Patient selection at this point is of paramount importance and will necessarily partly guide the intervention that the patient is offered to achieve the best outcome for them.
Hepatectomy remains the only potentially curative treatment for patients with BCRLM, with 5-year survival approaching 67% in selected patients [10] . Over the last decade or so, refinements in surgical technique and experience, concurrent advancements in perioperative care and systemic and/ or multi-modal therapies have led to significant improvements in the short-and long-term outcomes for patients undergoing liver resections for BCRLM [11, 12] .
Chemotherapy
The introduction of systemic chemotherapy in particular has increased the number of patients deemed to be resectable. Until the mid-1990s, 5-flourouracil (5-FU) was the mainstay of treatment, which yielded response rates of 20% without any survival benefit. However, advances in chemotherapeutic agents and delivery have changed the treatment of CRLM drastically [13] . Reduction in disease burden is possible with modern chemotherapies and so may offer a route by which patients can still get to resection eventually. Advances in chemotherapeutic agents and delivery have changed the treatment of liver metastases drastically and improved disease-free survival [13] . Preoperative chemotherapy allows complete resection in 12.5-32.5% of patients [14] with modern regimens which include FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and FOLFIRI (folinic acid, fluorouracil, and irinotecan). Capecitabine was the first oral agent licenced for use in BCRLM and is an effective alternative to intravenous 5-FU/leucovorin. The addition of oxaliplatin and irinotecan to the chemotherapeutic armamentarium has further increased the efficacy of systemic therapy and resulted in response rates of over 50%, with conversion of unresectable to resectable disease in up to 38% of cases [14] [15] [16] . Furthermore, the addition of monoclonal antibodies, such as cetuximab, has facilitated response rates of up to 80% in BCRLM. Modern chemotherapeutic regimes not only allow downsizing and increase resectability of disease but also enable the treatment of systemic disease to prevent distant recurrence, and as such is an expanding area of clinical intervention [17] .
However, neoadjuvant chemotherapy has been directly linked to postoperative complications due to their chemotoxic effects (steatohepatitis and sinusoidal obstruction) and therefore, the duration of chemotherapy and timing of surgery need to be carefully considered [18] . There is a lack of evidence to demonstrate the benefits of neoadjuvant chemotherapy specifically in BCRLM, except for a few small studies. Tanaka et al. proposed the use of intra-arterial neoadjuvant chemotherapy. Only 2 of 15 patients given neoadjuvant chemotherapy progressed during the treatment prior to surgery, but a higher complication rate was demonstrated in the neoadjuvant group. Overall survival at 1 and 5 years was 91.7 versus 79%, and 47.5 and 33.5% for neoadjuvant and non-neoadjuvant groups, respectively. They also found that microscopic invasion of portal structures was described on histological examination more frequently in the non-neoadjuvant group [19] .
One group has reported the use of transarterial chemoembolisation (TACE) in a highly selected group of patients (excluding > 70% liver volume affected, extrahepatic metastases, poor performance status) not responding to systemic chemotherapy. In selected patients, partial tumour response was reported in 16.7%, stable disease in 48.2% and progressive disease in 16.7% (by size measurement) with 1-year survival rate after chemoembolization of 62% (28% at 2 years); median survival from the start of chemoembolization treatment was 14.3 months [20] .
Drug-eluting beads delivering chemotherapy directly into the liver have been trialled with successful results for colorectal liver metastases. The prospective PARAGON II study evaluated beads in a single delivery to sub segment of the liver containing the tumour prior to resection in patients with easily resectable CRLMs. Pathological response rates demonstrated 76% of lesions showing major/complete pathological response, which is similar to six systemic cycles of FOLFOX/FOLFIRI [21] [22] [23] [24] . Delivery of local chemotherapy agent is thought to reduce systemic chemotoxic affect and could be combined alongside systemic agents in the future to maximise treatment for BCRLM and may deliver a chemotherapy combination similar to the FOLFOXIRI trial [25] (without severe chemotoxic load). The treatment may also be considered eventually for those patients who have had multiple cycles of first and second line chemotherapeutic agents; they may benefit from reduction in morbidity if they do get to resection.
Inadequate FRV
Management of patients with BCRLM remains challenging especially those with inadequate functional residual volume (FRV) [26] [27] [28] . The following techniques have been described to increase the opportunity for patients to progress from unresectable to resectable disease.
Portal Vein Embolisation
A small future remnant liver (portion remaining after resection) may preclude a major hepatectomy, and therefore, various methods have been developed to increase the size of it. Portal vein occlusion (PVO) or portal vein ligation is used to encourage hypertrophy of the future remnant liver portion and can be performed by ligating the ipsilateral portal vein at the time of initial surgery or radiologically. Metastases in the future remnant liver (FRL) are ideally resected prior to PVO being performed in the first stage because it has been suggested that metastases grew quicker in the remnant if PVO was performed after [29] . In the scenario of bilobar CRLM, PVO has been shown to be an effective and safe strategy to increase the safety of an extended hepatectomy. Several techniques for PVO have been reported including intraoperative portal vein ligation, trans-ileocolic PVE, and the percutaneous trans-hepatic PVE approach (which is now generally regarded as the standard). Furthermore, different embolization coils are also used (polyvinyl alcohol particles (PVA), coils, gelatin sponge, n-butyl cyanoacrylate and lipiodol, or fibrin glue) [30] .
Resection ± Ablation
Ablative techniques were developed to treat CRLM whilst limiting the damage to surrounding tissue and structures [31] . A variety of ablative methods induce high intratumoral temperatures, which cause the tissue necrosis in tumours up to approximately 5 cm in diameter [32] [33] [34] . Techniques include microwave (MWA) and, more commonly, radiofrequency ablation (RFA) [35] .
Initial concerns associated with ablative techniques such as thermal injury, septic sequelae and mechanical damage to local structures were quashed with a study from a group comparing hepatic resection plus RFA with hepatic resection only, post chemotherapy. They had no complications in the RFA group, and also a low local recurrence rate, and there were no overall significant differences in survival rate between the two groups [36] . There is a lack of evidence for RFA alone compared to hepatic resection. A meta-analysis for the treatment of bilateral CRC metastases with RFA compared with hepatic resection demonstrated significantly worse overall and disease-free survival in the RFA groups, but there was significant concern that these results were confounded by patient selection bias [37] . More recently the two have been more favourably compared, with overall survival rate not being significantly different between the two groups (although local recurrence was significantly higher in RFA group) [38] .
Recent data suggests that microwave ablation of BCRLM combined with resection in a single-stage procedure has comparable outcomes to two-stage hepatectomy (TSH). Two hundred and one patients from prospectively collected databases from multiple institutions were evaluated. Approximately half had MWA only; the others had a combination of microwave and radiofrequency ablation. Inpatient stay and complication rate were lower for the MWA group, and median overall survival was longer too, but disease-free survival length was similar for both groups. These outcomes were then compared to those reported of TSH in the literature. The overall comparison was favourable; in fact, short-term outcomes were better with similar disease-free survival, except for in one paper which was worse for 5-year survival [39] .
Cryoablation is now a mostly redundant ablative technique reliant on the delivery of liquid nitrogen or argon gas to the tumour to rapidly freeze the tissue. Due to high complication rate, in particular cryoshock, manifested by hypothermia, coagulopathy, respiratory failure and renal failure, and a greater recurrence rate than RFA [40] , the technique has become a less frequently considered option.
Operative Strategy

Two-Stage Hepatectomy
Metastectomy must be balanced in bilobar cases with preservation of functional volume of liver (FLR). This figure is approximately 20% of the total estimated liver volume for normal parenchyma, 30-60% if the liver is injured by chemotherapy, steatosis or hepatitis, or 40-70% in the presence of cirrhosis, depending on the degree of underlying hepatic dysfunction [41] . TSH was developed to reduce the overall risk of liver failure for those patients considered to be at the margins of resectability. Adam et al. published the first series of TSH in patients with unresectable bilobar CRLMs that were not amenable to resection in a single operation, even in combination with systemic chemotherapy or portal vein embolization [26] . Classically, TSH involves minor resections of the liver in the first stage, with major resection in the second stage, although this can be reversed, and is often accompanied by portal vein occlusion at the first stage to increase the volume of remnant liver, and/or neoadjuvant chemotherapy.
Mentha et al. managed 22 patients with two-stage hepatectomy with PVO and neoadjuvant chemotherapy. Of the suitable patients, only one did not have the second-stage treatment because of progression of lung metastases. For the remainder, the 3-and 5-year survival rates were 73 and 27%, respectively, although 18 had recurrence of disease in the liver. Additionally, a 'dangerous halo' of peripheral tumour growth of the metastasis in several patients was reported, thought to be due to interruption of chemotherapy for the surgery, or the immunosuppressive state that surgery itself induces, and suggested that a wider margin of resection be performed than the usual 1-mm clearance in the second stage [42] .
The major problem with the combined TSH procedure is the potential for progression of liver metastases between the two stages, which therefore precludes the second stage being performed. One study of 125 patients found 35% of patients could not proceed to the second stage to complete treatment [43] , so careful patient selection is imperative. Another study of 80 patients only had 42 complete the two stage process, with a 5-year survival rate of 32% in the completion group, despite the use of neo adjuvant and adjuvant chemotherapy [44] . A recent systematic review summarises the approach of ten groups to TSH and compares treatment combinations and outcomes, concluding that TSH is a safe treatment option in carefully selected patients in varied combination with portal vein ligation and/or chemotherapeutic agents [45] .
The results of laparoscopic TSH are not frequently described and are mostly still at feasibility stage. In 2015, one study reported results of 34 patients who underwent planned laparoscopic TSH. Eight patients dropped out because of disease progression but 26 completed the second stage laparoscopically. Rates of complication were comparable between the two laparoscopic stages, until 11 patients who had concomitant primary resection were excluded, when a significantly higher morbidity was found with the second operation (26 and 54%, respectively). Twenty-one patients in the completion group had recurrence; ten had intrahepatic only, the others had a combination of intra-and/or extrahepatic recurrence, and six patients went on to have a third hepatectomy. Overall survival rate for the group was 31% [46] . These results in a carefully selected small number are comparable to open series and demonstrate that the laparoscopic approach did not negatively affect the oncological course.
A modern approach to operative strategy is to consider TSH and ablative techniques as complementary treatments which may be offered to in combination to individually tailor treatment [36] . A recent international multicentre retrospective study assessed overall and disease-free outcomes for combined intraoperative ablation with hepatic resection. Eightyeight percent of the patients had bilateral CRC liver metastases, and 5-year overall survival was 37%. The combined approach described is proposed as a well-tolerated and effective approach for these patients [47] .
ALPPS Procedure
Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS) is the newest modification of the TSH technique and focuses on regeneration in the FRL, allowing resection of more advanced bilobar metastases. ALPPS is associated with a much shorter liver regeneration time (47-93% regeneration rate within 7-14 days), thus reducing time interval between surgeries, although this incurs an increase in complication rate. It is, again, a two-step procedure, the first being transection of the liver parenchyma along the intended line of resection and then 'cleaning' of future liver remnant by partial resection from all metastatic tumour tissue, plus PVO. The completion second stage is then performed following a period of 1-2 weeks. ALPPS offers two main advantages; like TSH, it reduces the risk of postoperative liver failure because the diseased lobe, left in place, acts as an auxiliary liver to assist the future liver remnant for the critical first week after resection, but it induces more hypertrophy than other techniques. It was first described in 2012 in a group of 22 patients, 14 of whom had CRC liver metastases, with similar short-term morbidity to TSH literature, although longer-term oncological outcomes were not assessed [48] . Schnitzbauer et al. reported a 74% volume increase of the remnant liver in a mean of 9 days. Early data from another group suggests that results of the ALPPS technique performed specifically for CRC metastases were comparable to conventional TSH with PVO. Their mortality at 2 years was 59% (with ongoing follow-up), but notably 10 of the 22 patients had failed PVO and salvage ALPPS was offered [49] . It is widely perceived however that the perioperative morbidity is higher in the ALPPS group compared to TSH [50] . Further versions of the technique have been described-radiofrequency assisted (RALLP) [51] and laparoscopic variations [52] , but these are case reports and series with limited outcome thus far. Other centres have concentrated on reducing the time taken overall from operative to oncological management, including performing the colorectal resection and the first-stage ALPPS simultaneously [53] , and 'liver first' surgery prior to colorectal resection [54] . The long-term follow-up of some of these patients is still ongoing, making comparison difficult. A research group is currently recruiting to directly compare THS Fig. 1 A systematic algorithm for treatment strategy in BCRLM. PVO, portal vein occlusion; ALPPS, associating liver partition and portal vein ligation for staged hepatectomy; HAI, hepatic artery infusion; DEBIRI, drug-eluting irinotecan beads with ALPPS in Zurich by randomised controlled trial. This will give real insight into the outcomes of both techniques for morbidity and mortality in this patient group.
Transplant
Prior to 1995, certain centres were offering liver transplant for CRC liver metastases but the outcomes was poor (overall survival of approximately 18%) so it was rejected as an option until recent years [55] , when a Norwegian group again offered liver transplant for to patients with unresectable liver metastases. The trial numbers were fairly small but initial results seemed positive. A comparison of first-line chemotherapy (NORDIC VII) with transplant (SECA study) found the overall survival at 5 years to be much better in the transplant group than the first-line chemotherapy group (56% compared to 9% respectively), although they showed similar disease/ progression-free survival of 8-10 months [56] . The same research group subsequently selected six cases with progressive disease on standard last-line chemotherapy and reported an overall survival of 44% at 5 years, although disease-free survival was reported as only 2.1-12.4 months [57] . A case report published during the same time period described a sole case of transplantation for unresectable CRC liver metastases in a young patient with liver failure but no extrahepatic evidence of disease who was still alive at 20 months, albeit with extrahepatic disease despite adjuvant chemotherapy post-transplant [58] . To our knowledge, there is no evidence in the literature of transplant being offered as an early intervention for patients with BCRLM. In selected cases, liver transplant may therefore be an option for a few patients with the potential to prolong overall (but not disease-free on current evidence) survival, thus potentially joining the ranks of 'transplant oncology' in a carefully selected and counselled few. However, in the majority of cases, transplant for BCRLM is unlikely to be a viable option, unlike in treatment for hepatocellular carcinoma. A mismatch of organ demand and supply perpetuates a lack of trial data, thus not supporting its use in the treatment algorithm for BCRLM.
Conclusions
Careful preoperative planning and disease staging help to personalise patient treatment for BCRLM. Ongoing improvements to better define patient selection criteria for each of these treatment strategies, combined with preoperative optimisation of both patient and tumour related factors, will help direct and target the appropriate treatment for each patient. Of the multiple treatment modalities, resection remains the most successful and frequently used for those patients with sufficient residual liver volume. In addition, ablative techniques, predominately RFA, have been shown to complement resection either concurrently or in multiple treatments over time. For those patients with insufficient liver volume, neoadjuvant chemotherapy has improved outcome for a group who potentially can be converted from unresectable to resectable, and continue their treatment. A small number may be suitable for the twostage techniques such as TSH and ALPPS, but transplant for BCRLM is rarely, if ever utilised. We propose the use of a treatment algorithm to tailor suitable treatment for every patient (see Fig. 1 ). Further well-designed longitudinal studies are required to better define patient selection criteria for each of these treatment strategies, combined with preoperative optimisation of both patient and tumour related factors.
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